Flexion Therapeutics (NASDAQ:FLXN) Downgraded by Raymond James to Market Perform

Flexion Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Flexion Therapeutics Downgraded by Raymond James on 10-12-21. In a note to investors, the firm issued a new rating of Market Perform. The analysts previously had rating of Strong-Buy.

Shares of Flexion Therapeutics traded up $0.13 on Tuesday, reaching $9.30. 226 shares of the stock traded hands, compared to its average volume of 2349362. Shares of Flexion Therapeutics were trading at $9.30 on Tuesday. The firm’s 50 day moving average is $6.02 and its 200 day moving average is $8.68.Flexion Therapeutics has a 12 month low of $9.06 and a 12 month high of $13.66. While on yearly highs and lows, Flexion Therapeutics’s today has traded high as $9.39 and has touched $9.06 on the downward trend. See More Analyst Rating at: RATING

Flexion Therapeutics Earnings and What to expect: 

Flexion Therapeutics last announced its earnings results on August 4th, 2021. The specialty pharmaceutical company reported ($0.44) EPS for the quarter, beating the consensus estimate of ($0.50) by $0.06. The firm had revenue of $28.18 million for the quarter, compared to the consensus estimate of $28.02 million. Flexion Therapeutics has generated ($2.53) earnings per share over the last year (($1.91) diluted earnings per share). Earnings for Flexion Therapeutics are expected to grow in the coming year, from ($1.81) to ($0.85) per share. Flexion Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Wednesday, November 3rd, 2021 based off prior year’s report dates.

Earnings for Flexion Therapeutics are expected to grow in the coming year, from ($1.81) to ($0.85) per share. The P/E ratio of Flexion Therapeutics is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Flexion Therapeutics is -4.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Flexion Therapeutics (NASDAQ:FLXN) Moving Average Technical Analysis

5 day Moving Average is $7.19 And 5 day price change is $3.24 (53.47%)  with average volume for 5 day average is 8,109,480. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $6.52 and 20 day price change is $3.37 (56.83%) and average 20 day moving volume is 2,896,475. 50 day moving average is $6.02  and 50 day price change is $3.05 ( 48.80%)  and with average volume for 50 days is : 1,972,692. 200 day moving average is $8.68  and 200 day price change is -$2.95 (-24.08%)  and with average volume for 200 days is : 1,059,814.

Other owners latest trading in Flexion Therapeutics :

  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 35,774 which equates to market value of $0.29M and appx 0.00% owners of Flexion Therapeutics
  • On 8/17/2021 shares held by Invesco Ltd. were 109,666 which equates to market value of $0.90M and appx 0.00% owners of Flexion Therapeutics
  • On 8/17/2021 shares held by Metropolitan Life Insurance Co NY were 13,414 which equates to market value of $0.11M and appx 0.00% owners of Flexion Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 89.77% for Flexion Therapeutics

See More Analyst Rating at: RATING